Spots Global Cancer Trial Database for tacrolimus

Every month we try and update this database with for tacrolimus cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant	NCT02333162	Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Hemat...	Fludarabine Pho... Melphalan Intensity-Modul... Total Marrow Ir... Allogeneic Hema... Peripheral Bloo... Allogeneic Bone... Tacrolimus Mycophenolate M... Laboratory Biom...	18 Years - 75 Years	University of Chicago
Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants	NCT01488253	Acute Leukemia ... Myelodysplastic... Leukemia, Myelo... Leukemia, Myelo...	Sirolimus Tacrolimus	20 Years - 60 Years	The Korean Society of Blood and Marrow Transplantation
Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies	NCT01203722	Hematologic Mal...	Fludarabine Cytoxan Total Body Irra... Allogeneic Bloo... Peripheral Bloo... Mycophenolate M... Sirolimus Tacrolimus	6 Months - 75 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation	NCT01810588	Hematologic Mal...	CliniMACS® CD34... Fludarabine Melphalan anti-thymocyte ... Rituximab Total Body Irra... Mycophenolate M... Tacrolimus	18 Years -	Weill Medical College of Cornell University
Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis	NCT03118492	Secondary Myelo...	Allogeneic Hema... Cyclophosphamid... Fludarabine Glycosylated Re... Laboratory Biom... Melphalan Mycophenolate M... Tacrolimus Total-Body Irra...	18 Years - 65 Years	City of Hope Medical Center
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome	NCT00445744	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child...	cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema...	- 65 Years	Fred Hutchinson Cancer Center
A Two Step Approach to Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Hematologic Malignancies-Increasing GVT Effects Without Increasing Toxicity	NCT03032783	Hematopoietic a...	Total-Body Irra... Donor Lymphocyt... Cyclophosphamid... Tacrolimus Mycophenolate M... Allogeneic Hema...	18 Years -	Thomas Jefferson University
Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant	NCT04177004	Allogeneic Hema... Hematopoietic a...	Allogeneic Hema... Cyclophosphamid... Etoposide Fractionated St... Goat Milk Palifermin Sirolimus Tacrolimus	12 Years -	City of Hope Medical Center
Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission	NCT00070135	Adult Acute Mye... Acute Myeloid L...	filgrastim Anti-Thymocyte ... busulfan fludarabine pho... methotrexate tacrolimus Allogeneic Hema...	60 Years - 74 Years	Alliance for Clinical Trials in Oncology
Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas	NCT00043979	Sarcoma	F-18 Fluorodeox... therapeutic all... cyclophosphamid... cyclosporine doxorubicin hyd... etoposide fludarabine pho... melphalan prednisone sirolimus tacrolimus vincristine sul... peripheral bloo... Filgrastim Peripheral Bloo...	5 Years - 35 Years	National Institutes of Health Clinical Center (CC)
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma	NCT02504359	Plasma Cell Leu... Recurrent Plasm...	Allogeneic Hema... Carmustine Cytarabine Etoposide Ixazomib Citrat... Melphalan Methotrexate Peripheral Bloo... Quality-of-Life... Tacrolimus	18 Years - 65 Years	OHSU Knight Cancer Institute
Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis	NCT02528877	Acute Myeloid L... Primary Myelofi... Primary Myelofi... Secondary Acute... Secondary Myelo...	Allogeneic Bone... Allogeneic Hema... Fludarabine Pho... Laboratory Biom... Melphalan Peripheral Bloo... Pharmacological... Ruxolitinib Pho... Sirolimus Tacrolimus	18 Years - 75 Years	City of Hope Medical Center
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation	NCT03680092	GVHD Hematologic Neo...	Cyclophosphamid... abatacept Methotrexate Tacrolimus	18 Years -	University of California, San Diego
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)	NCT01471444	Disorder Relate... Leukemia Transplantation...	Fludarabine Clofarabine Busulfan Thymoglobulin Stem Cell Infus... Tacrolimus Methotrexate	3 Years - 70 Years	M.D. Anderson Cancer Center
Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation	NCT04339101	Acute Leukemia Hematologic and... Myelodysplastic... Primary Myelofi... Secondary Myelo...	Fludarabine Itacitinib Adip... Melphalan Quality-of-Life... Questionnaire A... Sirolimus Tacrolimus	18 Years - 75 Years	City of Hope Medical Center
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies	NCT01341301	Hematologic Mal...	Total Body Irra... Donor Lymphocyt... Cyclophosphamid... Tacrolimus Mycophenolate m... Allogeneic hema... Laboratory biom...	18 Years -	Thomas Jefferson University
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD	NCT00914940	Graft Versus Ho... Leukemia Myelodysplastic...	Fludarabine Pho... Tacrolimus Thiotepa Total-Body Irra... Magnetic Affini... Peripheral Bloo... Allogeneic Hema... T Cell-Depleted...	14 Years - 55 Years	Fred Hutchinson Cancer Center
Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.	NCT03225417	Hematopoietic S... Multiple Myelom...	Ixazomib Tacrolimus Sirolimus Any prophylaxis...	18 Years -	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab	NCT00946023	Lymphoma B-cell Lymphoma Non Hodgkin Lym... Chronic Lymphoc...	Fludarabine Cyclophosphamid... Total body irra... Tacrolimus Mycophenolate M... Rituximab Allogeneic Bone...	1 Year - 75 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation	NCT03602898	Acute Lymphobla... Acute Myeloid L... Chronic Myelomo... Chronic Phase C... Hematopoietic a... Myelodysplastic... Myelofibrosis Myeloproliferat... Recurrent Acute... Recurrent Hodgk... Recurrent Non-H... Refractory Acut... Therapy-Related...	Anti-Thymocyte ... Busulfan Cyclophosphamid... Cyclosporine Fludarabine Pho... Methotrexate Peripheral Bloo... Quality-of-Life... Questionnaire A... Tacrolimus Total-Body Irra...	- 65 Years	Fred Hutchinson Cancer Center
Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab	NCT00946023	Lymphoma B-cell Lymphoma Non Hodgkin Lym... Chronic Lymphoc...	Fludarabine Cyclophosphamid... Total body irra... Tacrolimus Mycophenolate M... Rituximab Allogeneic Bone...	1 Year - 75 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	NCT00039377	Adult Acute Lym...	imatinib mesyla... methotrexate vincristine sul... leucovorin calc... peripheral bloo... autologous hema... allogeneic hema... total-body irra... tacrolimus filgrastim etoposide cyclophosphamid... cytarabine laboratory biom...	15 Years - 59 Years	National Cancer Institute (NCI)
Busulfan, Cyclophosphamide, and Melphalan or Busulfan and Fludarabine Phosphate Before Donor Hematopoietic Cell Transplant in Treating Younger Patients With Juvenile Myelomonocytic Leukemia	NCT01824693	Juvenile Myelom...	Allogeneic Hema... Busulfan Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Pharmacological... Tacrolimus	3 Months - 18 Years	Children's Oncology Group
Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)	NCT01303965	Multiple Myelom...	Sirolimus Tacrolimus Lenalidomide	18 Years -	Indiana University
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)	NCT02441803	Leukemia	Busulfan Fludarabine Clofarabine Total Body Irra... Thymoglobulin Stem Cell Infus... Cyclophosphamid... Tacrolimus Mycophenolate m... Decitabine Cytarabine Idarubicin	18 Years - 60 Years	M.D. Anderson Cancer Center
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients	NCT02877082	Acute Leukemia Chronic Lymphoc... Chronic Myeloge... Diffuse Large B... Follicular Lymp... Graft Versus Ho... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... Myelofibrosis Myeloproliferat... Small Lymphocyt...	Thymoglobulin Bortezomib Tacrolimus	18 Years - 75 Years	Emory University
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia	NCT01256398	Acute Lymphobla... Adult B Acute L...	Alemtuzumab Allogeneic Hema... Autologous Hema... Cyclophosphamid... Cytarabine Dasatinib Daunorubicin Hy... Dexamethasone Etoposide Phosp... Filgrastim Fludarabine Pho... In Vitro-Treate... Laboratory Biom... Leucovorin Calc... Melphalan Mercaptopurine Methotrexate Pegfilgrastim Pharmacological... Tacrolimus Vincristine Sul...	18 Years -	National Cancer Institute (NCI)
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)	NCT03970096	Acute Leukemia Acute Lymphobla... Acute Myeloid L... Myelodysplastic...	Total-Body Irra... Thiotepa Fludarabine Tacrolimus Allogeneic CD34... Methotrexate Cyclophosphamid... Peripheral Bloo... Cyclosporine Sirolimus Busulfan Bone Marrow Asp... Echocardiograph... Multigated Acqu... Biospecimen Col...	1 Year - 60 Years	Fred Hutchinson Cancer Center
Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients	NCT00499889	Leukemia	Imatinib Mesyla... Fludarabine (Fl... Busulfan Antithymocyte G... Tacrolimus Methotrexate Donor lymphocyt... Stem Cell Trans...	- 70 Years	M.D. Anderson Cancer Center
Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies	NCT02120157	Myeloablative C... HLA-mismatched ... Graft Survival Transplantation...	Cyclophosphamid... TBI Busulfan Unmanipulated B... Tacrolimus Mycophenolate m...	6 Months - 25 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Reduced-Intensity Conditioning for the Prevention of Treatment-Related Mortality in Patients Who Undergo a Hematopoietic Stem Cell Transplant	NCT05031897	Acute Lymphobla... Acute Myeloid L... Aplastic Anemia Chronic Lymphoc... Chronic Myelomo... Essential Throm... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloid Leukemi... Myeloid Neoplas... Non-Hodgkin Lym... Plasma Cell Mye... Polycythemia Ve... Small Lymphocyt...	Hematopoietic C... Mycophenolate M... Tacrolimus Cyclophosphamid... Total-Body Irra... Donor Lymphocyt... Fludarabine Melphalan	18 Years -	Thomas Jefferson University
2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies	NCT03712878	Hematopoietic a...	Total-Body Irra... Donor Lymphocyt... Cyclophosphamid... Allogeneic Hema... Tacrolimus Mycophenolate M...	18 Years -	Thomas Jefferson University
Allogeneic Stem Cell Transplant for CLL	NCT01629511	Allogeneic Hema... Chronic Lymphoc... Prolymphocytic ... Richter Syndrom...	Allogeneic Hema... Anti-Thymocyte ... Busulfan Clofarabine Filgrastim Gemcitabine Methotrexate Tacrolimus	18 Years - 70 Years	M.D. Anderson Cancer Center
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)	NCT01471444	Disorder Relate... Leukemia Transplantation...	Fludarabine Clofarabine Busulfan Thymoglobulin Stem Cell Infus... Tacrolimus Methotrexate	3 Years - 70 Years	M.D. Anderson Cancer Center
Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus	NCT00133367	Multiple Myelom... Non-Hodgkin's L... Hodgkin's Disea... Myelogenous Leu... Lymphoblastic L...	Tacrolimus Sirolimus G-CSF Antithymocyte g... Thymoglobulin Fludarabine Melphalan	18 Years - 65 Years	Massachusetts General Hospital
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	NCT02566304	Acute Myeloid L... Acute Myeloid L... Aplastic Anemia Chronic Myelomo... Hodgkin Lymphom... Indolent Non-Ho... Malignant Neopl... Myelodysplastic... Myeloproliferat... Plasma Cell Mye... Refractory Anem... Refractory Anem... Refractory Anem... Refractory Cyto... Refractory Cyto...	Fludarabine Total-Body Irra... T Cell-Depleted... Cyclophosphamid... Peripheral Bloo... Allogeneic Hema... Tacrolimus Mycophenolate m... Laboratory Biom...	18 Years -	Thomas Jefferson University
Sequential, Related Donor Partial Liver Transplantation Followed by Bone Marrow Transplantation for Hepatocellular Carcinoma (HCC)	NCT02702960	Fibrolamellar H... Hepatocellular ... Hepatocellular ...	living related ... Total body irra... Bone marrow tra... Cyclophosphamid... Mesna Filgrastim Tacrolimus mycophenolate m... Prednisone Antithymocyte g... fludarabine	16 Years - 65 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia	NCT01707004	Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... de Novo Myelody... Previously Trea... Recurrent Adult... Secondary Acute...	decitabine fludarabine pho... busulfan cyclophosphamid... tacrolimus mycophenolate m... filgrastim total-body irra... allogeneic bone... laboratory biom...	18 Years - 75 Years	University of Wisconsin, Madison
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant	NCT02333162	Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Hemat...	Fludarabine Pho... Melphalan Intensity-Modul... Total Marrow Ir... Allogeneic Hema... Peripheral Bloo... Allogeneic Bone... Tacrolimus Mycophenolate M... Laboratory Biom...	18 Years - 75 Years	University of Chicago
Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers	NCT00003572	Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	peripheral bloo... mycophenolate m... tacrolimus allogeneic bone... radiation thera...	18 Years - 70 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study of PD/PK/PG Relationships of Tacrolimus and Cyclosporin in Liver Transplant Patients	NCT01760356	End Stage Liver... Rejection Infection Malignancy Toxicity Diabetes		18 Years - 70 Years	UDA Centro Nacional Hepato-Bilio-Pancreático
Randomized Study: Standard of Care With or Without Atorvastatin for Prevention of GVHD for Matched Unrelated Donor BMT	NCT03066466	Acute Myeloid L... Acute Lymphocyt... Myelodysplastic...	Atorvastatin Methotrexate Tacrolimus	18 Years - 75 Years	Loyola University
Selective Depletion of CD45RA+T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD	NCT00914940	Graft Versus Ho... Leukemia Myelodysplastic...	Fludarabine Pho... Tacrolimus Thiotepa Total-Body Irra... Magnetic Affini... Peripheral Bloo... Allogeneic Hema... T Cell-Depleted...	14 Years - 55 Years	Fred Hutchinson Cancer Center
TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma	NCT02652468	Lymphoma	Fludarabine Pho... Mesna Cyclophosphamid... Total nodal irr... T Cell-Depleted... Allogeneic Hema... Peripheral Bloo... Mycophenolate M... Tacrolimus Rituximab	18 Years - 75 Years	University of Wisconsin, Madison
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome	NCT00445744	Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Myelo... de Novo Myelody... Essential Throm... Myelodysplastic... Polycythemia Ve... Previously Trea... Primary Myelofi... Recurrent Adult... Recurrent Child... Secondary Acute... Secondary Myelo... Secondary Myelo... Untreated Adult... Untreated Child...	cyclophosphamid... busulfan tacrolimus methotrexate cytogenetic ana... flow cytometry pharmacological... pharmacogenomic... peripheral bloo... allogeneic hema...	- 65 Years	Fred Hutchinson Cancer Center
Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide	NCT01342289	Hodgkin's Lymph... Leukemia Myelodysplastic... Multiple Myelom... Non Hodgkin's L...	Cyclophosphamid... Fludarabine Total body irra... Mycophenolate M... Tacrolimus 60 Tacrolimus 90 Tacrolimus 120 Bone marrow tra...	6 Months - 75 Years	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies	NCT02145403	Hematologic Mal... Relapse Graft-Versus-Ho...	Carfilzomib Tacrolimus	18 Years - 70 Years	University of Michigan Rogel Cancer Center
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome	NCT03670966	Acute Lymphobla... Acute Myeloid L... Acute Myeloid L... Chronic Myelomo... Myelodysplastic... Recurrent Acute... Recurrent Acute... Refractory Acut... Refractory Acut... Recurrent Mixed... Refractory Mixe... Hematopoietic a...	Astatine At 211... Cyclophosphamid... Total-Body Irra... Peripheral Bloo... Bone Marrow Tra... Mycophenolate M... Recombinant Gra... Fludarabine Pho... Tacrolimus Bone Marrow Asp... Biospecimen Col...	18 Years - 75 Years	Fred Hutchinson Cancer Center
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)	NCT00406393	Leukemia, Myelo... Leukemia, Lymph... Leukemia, Myelo... Myelodysplastic...	Tacrolimus Methotrexate Sirolimus	2 Years - 60 Years	Medical College of Wisconsin
A Two-Step Approach to Bone Marrow Transplant Using Cells From A Partially-Matched Relative	NCT00429143	Hematologic Mal...	Total Body Irra... Donor Lymphocyt... Cyclophosphamid... Tacrolimus Mycophenolate M... Hematopoietic S...	18 Years -	Thomas Jefferson University
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia	NCT01168219	Acute Myeloid L... Adult Acute Meg... Adult Acute Mon... Adult Acute Mon... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Erythrole... Adult Pure Eryt... Alkylating Agen... de Novo Myelody... Myelodysplastic... Myelodysplastic... Recurrent Adult... Secondary Myelo...	Allogeneic Hema... Anti-Thymocyte ... Azacitidine Busulfan Fludarabine Pho... Laboratory Biom... Methotrexate Pharmacological... Tacrolimus	18 Years - 74 Years	National Cancer Institute (NCI)
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis	NCT04370301	Primary Myelofi... Secondary Myelo...	Cyclophosphamid... JAK Inhibitor Fludarabine Recombinant Gra... Melphalan Mycophenolate M... Peripheral Bloo... Tacrolimus Total-Body Irra... Computed Tomogr... Magnetic Resona... Bone Marrow Bio... Bone Marrow Asp... Biospecimen Col... Echocardiograph... Multigated Acqu...	18 Years -	Fred Hutchinson Cancer Center
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children	NCT01858740	Accelerated Pha... Acute Biphenoty... Acute Leukemia ... Acute Undiffere... Adult Acute Lym... Adult Acute Mye... Blast Phase Chr... Childhood Acute... Childhood Acute... Chronic Myeloge... Myelodysplastic... Myelodysplastic... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Adul... Refractory Chil...	Allogeneic Hema... Fludarabine Pho... Laboratory Biom... Methotrexate Peripheral Bloo... T Cell-Depleted... Tacrolimus Thiotepa Total-Body Irra...	- 21 Years	Fred Hutchinson Cancer Center
High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant	NCT01534143	Refractory Mult... Stage I Multipl... Stage II Multip... Stage III Multi...	pharmacological... tacrolimus sirolimus anti-thymocyte ... fludarabine pho... busulfan bortezomib allogeneic hema... laboratory biom...	18 Years - 70 Years	Barbara Ann Karmanos Cancer Institute
Immunotherapy of the Paraneoplastic Syndromes	NCT00378326	Paraneoplastic ...	Tacrolimus	14 Years -	Rockefeller University
A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors	NCT01349101	Hematological M...	Total Body Irra... Cyclophosphamid... Tacrolimus Mycophenolate m... Fludarabine Busulfan Hematopoietic s...	18 Years -	Thomas Jefferson University
Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer	NCT00296023	Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	anti-thymocyte ... filgrastim therapeutic all... busulfan fludarabine pho... methotrexate tacrolimus nonmyeloablativ... peripheral bloo...	18 Years - 75 Years	University of California, San Francisco
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation	NCT00720629	Graft Versus Ho...	Visilizumab Tacrolimus Methotrexate Antithymocyte g... Tacrolimus Methotrexate	18 Years - 60 Years	H. Lee Moffitt Cancer Center and Research Institute
Safety and Efficacy of ProHema Modulated Umbilical Cord Blood Units in Subjects With Hematologic Malignancies.	NCT00890500	Hematologic Mal... Allogeneic Stem...	Fludarabine Melphalan Antithymocyte G... Sirolimus Tacrolimus	18 Years - 65 Years	Fate Therapeutics
Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation	NCT00720629	Graft Versus Ho...	Visilizumab Tacrolimus Methotrexate Antithymocyte g... Tacrolimus Methotrexate	18 Years - 60 Years	H. Lee Moffitt Cancer Center and Research Institute
Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia	NCT01008462	B-Cell Prolymph... Hypodiploidy Loss of Chromos... Plasma Cell Leu... Progression of ... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Recurrent Chron... Recurrent Plasm... Recurrent Small... Refractory Chil... Refractory Chro... Refractory Non-... Refractory Plas... Refractory Smal... t(14;16) t(4;14) T-Cell Prolymph... Waldenstrom Mac...	Allogeneic Bone... Allogeneic Hema... Autologous Hema... Autologous-Allo... Carmustine Cyclophosphamid... Cytarabine Etoposide Fludarabine Pho... Laboratory Biom... Melphalan Mycophenolate M... Peripheral Bloo... Tacrolimus Total-Body Irra...	- 75 Years	Fred Hutchinson Cancer Center
Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer	NCT00782379	Leukemia Lymphoma Myelodysplastic...	busulfan cyclophosphamid... fludarabine pho... mycophenolate m... tacrolimus allogeneic hema... peripheral bloo...	18 Years - 60 Years	Northside Hospital, Inc.
Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia	NCT04262843	Acute Lymphobla... Acute Myeloid L... High Risk Myelo... Myelodysplastic...	Cyclophosphamid... Fludarabine Fludarabine Pho... Granulocyte Col... Hematopoietic C... Intensity-Modul... Mycophenolate M... Tacrolimus	12 Years - 60 Years	City of Hope Medical Center
NK Cells in Cord Blood Transplantation	NCT01619761	Accelerated Pha... Acute Biphenoty... Acute Lymphobla... Acute Myeloid L... Chronic Phase C... DS Stage II Pla... DS Stage III Pl... High Grade B-Ce... ISS Stage II Pl... ISS Stage III P... Myelodysplastic... Recurrent Acute... Recurrent Acute... Recurrent Chron... Recurrent Hodgk... Recurrent Non-H... Recurrent Small... Refractory Acut... Refractory Chro... Refractory Hodg... Refractory Non-... Refractory Smal... Secondary Acute... Therapy-Related... Therapy-Related...	Allogeneic Hema... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Lenalidomide Melphalan Mycophenolate M... Natural Killer ... Rituximab Tacrolimus Total-Body Irra... Umbilical Cord ...	- 75 Years	M.D. Anderson Cancer Center
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis	NCT06001385	Acute Lymphobla... Acute Myeloid L... Acute Leukemia Myelodysplastic... Chronic Myeloid... Chronic Lymphoc... Myeloproliferat... Lymphoma Chronic Myelomo... Pro-Lymphocytic... Myelofibrosis	Busulfan Fludarabine PBSC Hematopoie... Post-Transplant... Mesna Tacrolimus Mycophenolate M... Patient Reporte... Melphalan Total-body irra... Cyclophosphamid...	18 Years -	Center for International Blood and Marrow Transplant Research
Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies	NCT00857389	Stem Cell Trans... Leukemia Lymphoma	Thiotepa Clofarabine Busulfan Allogeneic Stem... Thymoglobulin (... G-CSF (Filgrast... Tacrolimus Methotrexate Cyclophosphamid... Mesna	- 60 Years	M.D. Anderson Cancer Center
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome	NCT06287944	Acute Lymphobla... Acute Myeloid L... Myelodysplastic...	Actinium Ac 225... Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Computed Tomogr... Daratumumab Echocardiograph... Fludarabine Hematopoietic C... Indium In 111-D... Melphalan Multigated Acqu... Radionuclide Im... Single Photon E... Sirolimus Tacrolimus Total Marrow an...	18 Years -	City of Hope Medical Center
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies	NCT01471067	Blood And Marro... Leukemia Lymphoma Transplantation... Transplantation...	Melphalan Fludarabine Mycophenolate m... Tacrolimus Cord Blood Infu... Rituximab ATG Busulfan Clofarabine Total Body Irra...	1 Year - 80 Years	M.D. Anderson Cancer Center
Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma	NCT00028600	Multiple Myelom... Plasma Cell Neo...	filgrastim CD34+ cells cyclophosphamid... fludarabine pho... melphalan methotrexate tacrolimus	- 64 Years	Alliance for Clinical Trials in Oncology
Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma	NCT04205240	Recurrent Plasm...	Allogeneic Hema... Cyclophosphamid... Daratumumab Fludarabine Melphalan Mycophenolate M... Tacrolimus	18 Years - 75 Years	Ohio State University Comprehensive Cancer Center
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene	NCT01875237	Leukemia Myeloma Myeloproliferat...	Fludarabine Melphalan Alemtuzumab Stem Cell infus... Tacrolimus Mini Methotrexa... G-CSF Donor Lymphocyt... AP1903 Methylprednisol... Questionnaire	18 Years - 65 Years	M.D. Anderson Cancer Center
Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant	NCT03531281	Hematopoietic a... Hematopoietic C...	Allogeneic Hema... Cyclophosphamid... Etoposide Goat Milk Laboratory Biom... Palifermin Sirolimus Tacrolimus Total-Body Irra...	12 Years - 60 Years	City of Hope Medical Center
Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis	NCT03426969	Primary Myelofi... Secondary Myelo...	Cyclophosphamid... Filgrastim Fludarabine Pho... Hematopoietic C... Melphalan Mycophenolate M... Tacrolimus Total-Body Irra...	18 Years - 70 Years	M.D. Anderson Cancer Center
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia	NCT01885689	Adult Acute Lym... Acute Myeloid L... Adult Acute Mye... Myelodysplastic... Secondary Myelo... Chronic Myelomo... Therapy-Related...	clofarabine melphalan allogeneic hema... tacrolimus sirolimus Pharmacological...	18 Years - 75 Years	City of Hope Medical Center
Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant	NCT04022239	Hematopoietic a...	Allogeneic Hema... Bendamustine Cyclophosphamid... Filgrastim-sndz Fludarabine Melphalan Mycophenolate M... Rituximab Tacrolimus Total-Body Irra...	18 Years - 70 Years	M.D. Anderson Cancer Center
Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease.	NCT03225417	Hematopoietic S... Multiple Myelom...	Ixazomib Tacrolimus Sirolimus Any prophylaxis...	18 Years -	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma	NCT04205240	Recurrent Plasm...	Allogeneic Hema... Cyclophosphamid... Daratumumab Fludarabine Melphalan Mycophenolate M... Tacrolimus	18 Years - 75 Years	Ohio State University Comprehensive Cancer Center
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT	NCT02627573	Leukemia, Chron... Myelodysplastic... Leukemia, Myelo...	Unrelated allog... Busulfan Fludarabine mon... Tacrolimus Mycophenolate m... Cyclophosphamid... Thymoglobulin	18 Years - 75 Years	St. Petersburg State Pavlov Medical University
Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous or Acute Leukemia	NCT00002831	Leukemia	Filgrastim Busulfan Cyclophosphamid... Cyclosporine Decitabine (DAC... Methotrexate Methylprednisol... Tacrolimus Allogeneic Bone... Peripheral Bloo...	15 Years - 55 Years	M.D. Anderson Cancer Center
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD	NCT02220985	Accelerated Pha... Acute Biphenoty... Acute Leukemia ... Acute Undiffere... Allogeneic Hema... Blast Phase Chr... Blastic Plasmac... Childhood Acute... Childhood Acute... Donor Lymphoblastic L... Myelodysplastic... Myelodysplastic... Myelodysplastic... Recurrent Acute... Recurrent Acute... Recurrent Child... Recurrent Child... Recurrent Chron... Refractory Acut... Refractory Acut... Acute Lymphobla... Acute Myeloid L...	Allogeneic Hema... Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Methotrexate Mycophenolate M... Peripheral Bloo... Peripheral Bloo... Tacrolimus Thiotepa Total-Body Irra...	- 60 Years	Fred Hutchinson Cancer Center

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world:

Spots Global Cancer Trial Database for tacrolimus

Every month we try and update this database with for tacrolimus cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for tacrolimus cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.